1
described, 8 of which (89%) occurred within the last 3 years. Three patients had suppression burst (SB) activity on EEG and all died (cerebral performance category [CPC] ϭ 5). The remaining 6 patients did not have SB pattern on EEG, 2 had CPC 1-2 (good) outcome and at least 7 Hz background on EEG. Of these, 4 patients had a CPC outcome of 5 and EEGs with ␦, , or ␣ background cerebral activity except 1 patient with generalized periodic epileptiform discharges (GPEDs). Therefore, SB pattern and GPEDs on EEG had 100% specificity for poor prognosis whereas other EEG rhythms had poor specificity and sensitivity for eventual outcome. 
ANTI-JC VIRUS ANTIBODIES IN A LARGE GERMAN NATALIZUMAB-TREATED MS COHORT
Hamid Zahednasab, Tehran, Iran: Trampe et al. 1 should be commended for their investigation into the rate of seropositivity of the anti-JC virus (JCV) antibodies in a German multiple sclerosis (MS) cohort treated with natalizumab. Further points need to be considered. Trampe et al. 1 investigated the rate of anti-JCV antibodies by using a confirmatory 2-step ELISA on 2,782 blood samples. Although the serum sample is a good option for the detection of anti-JCV antibodies by ELISA method, it would be more accurate if they measured JVC-DNA in the urine samples of patients with MS. It has been shown that the subjects who developed progressive multifocal leukoencephalopathy (PML) in the longitudinal cohort had detectable JCV-DNA in urine at all time points whereas serum or blood from patients with PML were always negative before the onset of disease.
2 This same report also showed that 4 subjects with JCV-DNA in urine and undetectable anti-JCV antibodies were retested for anti-JCV antibodies and 3 out of 4 resulted positive. Thus, it would be more plausible that testing JCV-DNA in urine is complementary to testing anti-JCV antibodies to monitor patients at risk of PML.
Patients taking IFN-␤ should be excluded from this study. It has been shown that the administration of IFN-␤ can lead to the reduction of JCV genome 3 and may result in a false-negative due to decreasing the JCV titer.
Author Response: Anne-Kathrin Trampe, Anke Stroet, Ralf Gold, Andrew Chan, Bochum, Germany: Dr. Zahednasab indicates that several studies have investigated JCV-DNA in urine as a potential Editors' Note: In reference to "Anti-JC virus antibodies in a large German natalizumab-treated MS cohort" by Trampe et al., Mr. Zahednasab discusses why testing for anti-JC virus antibodies in urine may be more effective than serum sampling. He also comments that patients taking IFN-␤ should have been excluded as it can falsely decrease those patients' JCV titers. The authors uphold their methodology, responding that urinary JCV-DNA has a low predictive value and that, by not excluding patients with previous IFN-␤ treatment, their cohort is most representative of clinical practice.
Megan Alcauskas, MD, and Robert C. Griggs, MD
Section Editor Robert C. Griggs, MD tool for PML risk stratification. 2, 4, 5 In one of the largest studies, 5 urinary JCV-DNA could not be detected in 1 of 3 patients who subsequently developed PML; urinary JCV excretion was detected frequently and did not increase during natalizumab treatment. Thus, predictive values of either positive or negative tests appear to be low. 5 Using urinary JCV-DNA analysis, a false-negative rate of the 2-step anti-JCVantibody ELISA of approximately 2.7% can be calculated. 4 Due to lack of biomaterial we were not able to determine the rate of false-negative findings of anti-JCV serology in our cohort. Given the current label of natalizumab in Germany, the majority of patients have undergone immunomodulatory pretreatment (e.g., with IFN-␤). 6 Since we aimed to investigate the potential utility of anti-JCV serology in clinical practice, we did not exclude these patients from analysis.
1 Furthermore, our data do not indicate an immunomodulatory pretreatment effect on anti-JCV serostatus or titer (median normalized optical density [25%-75% percentile]: untreated 0.542 [0.207-1.080], n ϭ 59; immunmodulators: 0.579 [0.290 -0.974], n ϭ 786, p ϭ NS). 1 We agree that further investigation is needed to fully elucidate the predictive value of anti-JCV-antibody testing in PML risk stratification.
